CVAC Stock Overview
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CureVac N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.31 |
| 52 Week High | US$12.36 |
| 52 Week Low | US$2.22 |
| Beta | 2.5 |
| 1 Month Change | -21.43% |
| 3 Month Change | -35.29% |
| 1 Year Change | -68.44% |
| 3 Year Change | -97.99% |
| 5 Year Change | n/a |
| Change since IPO | -95.87% |
Recent News & Updates
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20
CureVac: No Momentum In Sight
Mar 08Recent updates
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20CureVac: No Momentum In Sight
Mar 08What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
Aug 26CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 14Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
May 01Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
Apr 29An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Jan 08CureVac BV reports Q2 results
Aug 18CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
Jul 05Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
May 02A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Oct 28CureVac: Wait For Concrete News Before Investing
Sep 01CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy
Jun 16An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Jun 13CureVac tumbles on potential delay for European decision on its COVID-19 shot
Jun 08CureVac: The Moment Of Truth Arrives
Jun 01CureVac BV reports Q1 results
May 26CureVac Could Soon Join The Fight Against COVID-19
May 10CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability
May 02How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?
Mar 03CureVac expands Phase 1 Trial for CV8102 in advanced Melanoma
Feb 04Analysts Are Optimistic We'll See A Profit From CureVac N.V. (NASDAQ:CVAC)
Jan 27CureVac's COVID-19 vaccine shows promise in preclinical study of non-human primates
Jan 11CureVac, Bayer agree to COVID-19 vaccine alliance - report
Jan 07Have Insiders Been Buying CureVac N.V. (NASDAQ:CVAC) Shares?
Dec 23Curevac advances COVID-19 vaccine candidate to Phase 3 trial
Dec 21CureVac commences global mid-stage trial for COVID-19 vaccine candidate
Dec 14Shareholder Returns
| CVAC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.3% | 0.4% | 1.0% |
| 1Y | -68.4% | 0.9% | 21.9% |
Return vs Industry: CVAC underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: CVAC underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| CVAC volatility | |
|---|---|
| CVAC Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CVAC's share price has been volatile over the past 3 months.
Volatility Over Time: CVAC's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 977 | Alexander Zehnder | www.curevac.com |
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck.
CureVac N.V. Fundamentals Summary
| CVAC fundamental statistics | |
|---|---|
| Market cap | US$517.26m |
| Earnings (TTM) | -US$324.28m |
| Revenue (TTM) | US$46.00m |
11.2x
P/S Ratio-1.6x
P/E RatioIs CVAC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVAC income statement (TTM) | |
|---|---|
| Revenue | €42.88m |
| Cost of Revenue | €125.75m |
| Gross Profit | -€82.87m |
| Other Expenses | €219.43m |
| Earnings | -€302.30m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.35 |
| Gross Margin | -193.25% |
| Net Profit Margin | -704.99% |
| Debt/Equity Ratio | 0% |
How did CVAC perform over the long term?
See historical performance and comparison